697762-60-0

Basic information

• Product Name: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate
• Synonyms: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate;7-Fluoro-1,4-dihydro-1-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-6-iodo-4-oxo-3-quinolinecarboxylic acid ethyl ester;3-Quinolinecarboxylic acid, 7-fluoro-1,4-dihydro-1-[(1S)-1-(hydroxyMethyl)-2-Methylpropyl]-6-iodo-4-oxo-, ethyl ester;(S)-Ethyl 7-fluoro-1-(1-hydroxy-3-methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxyla;(S)-Ethyl 7-fluoro-1-(1-hydroxy-3-methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carbox
• CAS NO: 697762-60-0
• Molecular Formula: C₁₇H₁₉FINO₄
• Molecular Weight: 447.2399332
• EINECS: -0
• Mol File: 697762-60-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 524.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.605±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.31±0.10(Predicted)
• CAS DataBase Reference: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(697762-60-0)
• EPA Substance Registry System: (S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate(697762-60-0)

Safety Data

• Hazardous Substances Data: 697762-60-0(Hazardous Substances Data)

Usage

General Description

(S)-ethyl 7-fluoro-1-(1-hydroxy-3-Methylbutan-2-yl)-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylate, also known as ethyl levofloxacin, is a chemical compound that belongs to the class of fluoroquinolone antibiotics. It is a semisynthetic derivative of the naturally occurring compound, ofloxacin. Ethyl levofloxacin is used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. Its mechanism of action involves inhibiting the bacterial DNA gyrase, which prevents the bacteria from replicating and ultimately leads to their death. Ethyl levofloxacin is typically administered orally and is well-absorbed into the bloodstream, allowing it to effectively target and eliminate the offending bacteria. However, it is important to note that this compound can have potential side effects and should be used with caution, particularly in individuals with a history of tendon disorders or other risk factors.

Upstream product

• 72-18-4 L-valine 
• 161531-51-7 2,4-difluoro-5-iodobenzoic acid 
• 1583-58-0 2,4-difluoro-benzoic acid 
• 1131640-54-4 (S,Z)-ethyl 2-(2,4-difluoro-5-iodobenzoyl)-3-(1-hydroxy-3-methylbutan-2-ylamino)acrylate 
• 697762-59-7 C₁₇H₂₀F₂INO₄ 
• 697762-39-3 ethyl 2-(2,4-difluoro-5-iodobenzoyl)-3-(dimethylamino)acrylate 
• 2026-48-4 (S)-valinol 

Downstream Products

• 1261283-91-3 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1261283-94-6 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid dicyclohexylamine salt 
• 1261283-95-7 1(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-97-9 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261283-99-1 1-(S)-[1-(tert-butyldimethylsilanyloxymethyl)-2-methylprop-1-yl]-6-(3-chloro-2-fluorobenzyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1261284-01-8 6-(3-chloro-2-fluorobenzyl)-7-methoxy-1-[1-(S)-2-methyl-1-(tetrahydropyran-2-yloxymethyl)prop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 697762-63-3 C₂₄H₂₄ClF₂NO₄ 
• 697762-62-2 (S)-ethyl 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-(1-(methoxycarbonyloxy)-3-methylbutan-2-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 697762-66-6 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-[1-(S)-tert-butyldimethylsilyloxymethyl-2-methylprop-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 697761-98-1 elvitegravir 
• 869893-92-5 6-(3-chloro-2-fluorobenzyl)-7-fluoro-1-((S)-1-hydroxymethyl-2-methylprop-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 870294-02-3 1-((2S)-1-tert-butyldimethylsilyloxy-3-methylbutan-2-yl)-7-fluoro-6-iodo-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF ELVITEGRAVIR

The present invention relates to improved process for the preparation of elvitegravir (12), wherein the compound of formula (6) is protected with suitable protecting agents and further reacted with formula (9) in the presence of tetrakis(triphenylphosphin

DEUTERATED 4 -OXOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTION

This invention relates to novel compounds that are 4-oxoquinoline derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 4-oxoquinoline derivatives that are derivatives of elvitegravir. This invention

6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor

The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV